Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 1:10:207-216.
doi: 10.2147/CMAR.S143019. eCollection 2018.

Advances in the treatment of soft tissue sarcoma: focus on eribulin

Panagiotis Koliou #  1 , Vasilios Karavasilis #  1 , Maria Theochari  2 , Seth M Pollack  3 , Robin L Jones  4 , Khin Thway  4
Affiliations
Review

Advances in the treatment of soft tissue sarcoma: focus on eribulin

Panagiotis Koliou et al. Cancer Manag Res. .

Abstract

Eribulin mesylate is a synthetic derivative of halichondrin B isolated from a marine sponge. Its mechanism of action is through microtubule inhibition, which is different from that of taxanes. Eribulin has been approved for the treatment of metastatic breast cancer and more recently for non-operable or metastatic liposarcoma in patients who have received prior anthracycline chemotherapy. The major side effects of eribulin are bone marrow suppression including neutropenia, leukopenia, anemia, and fatigue/weakness, which can be well managed. In this article, we reviewed evidence from the latest published data on eribulin and its use in the treatment of soft tissue sarcomas. We explored the drug's mechanism of action, pharmacodynamics, pharmacokinetics, and metabolism. Lastly, we reviewed all preclinical studies as well as clinical trials that investigated eribulin.

Keywords: chemotherapy; eribulin; sarcoma.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Molecular structures of halichondrin B and eribulin. Note: Reproduced from National Center for Biotechnology Information. Pubchem Open Chemistry Database –Compound Summary for CID 11354606. https://pubchem.ncbi.nlm.nih.gov/compound/11354606, and https://pubchem.ncbi.nlm.nih.gov/compound/5488895.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jo VY, Fletcher CD. WHO classification of tumours of soft tissue an update based on the 2013 (4th) edition. Pathology. 2014;46(2):95–104. - PubMed
    1. Colombo C, Randall RL, Andtbacka RHI, Gronchi A. Surgery in soft tissue sarcoma: more conservative in extremities, more extended in the retroperitoneum. Expert Rev Anticancer Ther. 2012;12(8):1079–1087. - PubMed
    1. Crago AM, Brennan MF. Principles in management of soft tissue sarcoma. Adv Surg. 2015;49:107–122. - PMC - PubMed
    1. Loizos N, Xu Y, Huber J, et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther. 2005;4(3):369–379. - PubMed
    1. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488–497. - PMC - PubMed